

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/24625

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00, 15/00, 15/87; A61K 48/00  
US CL : 514/44; 435/320.1, 325, 455

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/44; 435/320.1, 325, 455

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ILAN. Y. et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA. March 1997, Vol. 94, page 2587-2592, see entire document.	3, 5-9, 19-27, 37-45
Y	KAGAWA. S. et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther. 2000, Vol. 7, pages 75-79, see entire document.	1-2, 5-18, 37-45
Y	BORNER. C. et al. The protein bcl-2alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J. Cell. Biol. August 1994, Vol. 126, No. 4, pages 1059-1068, see entire document.	4-9, 28-45
Y	US 5,691,179 A (KORSMEYER) 25 November 1997 (25.11.1997), see entire document.	1-2, 4-18, 28-45
Y	RABINOVITCH. A. et al. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction. Diabetes. June 1999, Vol. 48, pages 1223-1229, see entire document.	4-9, 28-45

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

17 May 2004 (17.05.2004)

Date of mailing of the international search report

27 MAY 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Valerie Bell-Haworth

Telephone No. 703-308-1235

**INTERNATIONAL SEARCH REPORT**

PCT/US03/24625

**Continuation of B. FIELDS SEARCHED Item 3:**

DIALOG-Medline, Embase, Cancerlit, Scisearch, Biosis; BRS/EAST-USPatful, EPO, JPO, Derwint  
search terms: bax, bcl-2, delta bcl-2, truncated bcl-2, adenovirus, e3, e3gp19k, autoimmum?, diabetes, plasmid?, vector?, retrovir?,  
cdna